← Back to headlines
Barclays Assigns Overweight Rating to SAB Biotherapeutics Inc.
Barclays has issued an 'Overweight' rating for SAB Biotherapeutics Inc. (SABS), indicating a positive outlook for the company's stock.
30 Jun, 16:34 — 30 Jun, 16:34
Sources
Showing 1 of 1 sources
